COVID-19, SARS-CoV-2 Infection
Conditions
Keywords
antibodies, cell immunity
Brief summary
The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in specific subjects cohorts.
Detailed description
The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in four specific cohorts: participants with chronic illness, healthy volunteers participating in the Study of the Czech Academy of Science, healthcare workers, and healthy volunteers that participated in the Herd Immunity Study SARS-CoV-2-CZ-Preval in May 2020. The primary aim of the study is to estimate the number of people with anti-SARS-CoV-2-antibodies, i.e., people with COVID-19 history, or with vaccination against COVID-19. Antibodies test will focus on two main proteins of virus SARS-CoV-2: S-protein and N-protein. The secondary aims of the study are: * quantitative analysis of cellular immunity and the other relevant markers, * estimation of the proportion of participants with asymptomatic COVID-19 infection * quantification of anti-SARS-CoV-2 antibodies and cell immunity according to individual risk factors.
Interventions
DIAGNOSTIC_TESTQuantitative analysis of SARS-CoV-2 antibodies
The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).
DIAGNOSTIC_TESTCellular immunity
Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.
Sponsors
Ministry of Health, Czech Republic
The National Institute of Public Health
The Institute of Molecular and Translational Medicine, Czech Republic
University Hospital Olomouc
Institute for Clinical and Experimental Medicine
Thomayer University Hospital
Czech Academy of Sciences
Palacky University
Institute of Health Information and Statistics of the Czech Republic
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* signed Informed consent * willingness to complete the study questionnaire * demographic criteria - age 18 years old and more * clinical criteria - without acute health problems * time criteria - sample collection in the defined period time
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Detection of a number of subjects with IgG anti-SARS-CoV-2 antibodies | September-October 2021 | The primary outcome is to quantify the prevalence of participants with IgG anti-SARS-CoV-2 antibodies in the specified subjects cohorts. |
Countries
Czechia
Outcome results
None listed